1. |
Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. 2020: 2020.02. 07.937862.
|
2. |
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant, 2020, 39(5): 405-407.
|
3. |
马文君, 贾换. 丙种球蛋白联合地塞米松治疗重症肺炎的效果. 河南医学研究, 2020, 29(7): 1259-1260.
|
4. |
Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect, 2020, 81(1): e13-e20.
|
5. |
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223): 473-475.
|
6. |
Hazbun ME, Faust AC, Ortegon AL, et al. The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: a series of 21 consecutive cases. Crit Care Explor, 2020, 2(6): e0145.
|
7. |
Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis, 2020, 71(16): 2114-2120.
|
8. |
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 2015, 4(1): 1.
|
9. |
姜利, 潘纯, 桑岭, 等. 重症新型冠状病毒肺炎管理专家推荐意见. 中华重症医学电子杂志, 2020, 6(1): 1-11.
|
10. |
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
|
11. |
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-560.
|
12. |
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med, 2021, 384(8): 693-704.
|
13. |
Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr, 2021, 133(7-8): 303-311.
|
14. |
Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA, 2020, 324(13): 1317-1329.
|
15. |
Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA, 2020, 324(13): 1298-1306.
|
16. |
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA, 2020, 324(13): 1307-1316.
|
17. |
Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis, 2021, 72(9): e373-e381.
|
18. |
Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J, 2020, 56(6): 2002808.
|
19. |
Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol, 2020, 20(10): 587-588.
|
20. |
Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne), 2020, 7: 170.
|
21. |
高安, 陆圣威, 陈丽, 等. 糖皮质激素在重症新型冠状病毒肺炎治疗中的安全性荟萃分析. 中国感染与化疗杂志, 2021, 21(4): 411-417.
|
22. |
Cheng W, Li Y, Cui L, et al. Efficacy and safety of corticosteroid treatment in patients with COVID-19: a systematic review and meta-analysis. Front Pharmacol, 2020, 11: 571156.
|
23. |
Gangopadhyay KK, Mukherjee JJ, Sinha B, et al. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): a meta-analysis. Available at: https://www.medrxiv.org/content/10.1101/2020.04.17.20069773v1.
|
24. |
Lu S, Zhou Q, Huang L, et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Ann Transl Med, 2020, 8(10): 627.
|
25. |
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA, 2020, 324(13): 1330-1341.
|